Table 1.
Patient information in this study.
| gender | |
| male | 314 (68.41%) |
| female | 145 (31.59%) |
| age at surgery | |
| ≤60 | 270 (58.82%) |
| >60 | 189 (41.18%) |
| tumour size | |
| <4.0 | 66 (14.38%) |
| ≥4.0 | 393 (85.62%) |
| tumour location | |
| upper third | 113 (24.62%) |
| middle third | 117 (25.49%) |
| lower third | 201 (43.79%) |
| more than 2/3 stomach | 28 (6.10%) |
| depth of tumour invasion (T stage) | |
| T1 | 5 (1.09%) |
| T2 | 46 (10.02%) |
| T3 | 284 (61.87%) |
| T4 | 124 (27.02%) |
| number of metastatic lymph nodes (N stage) | |
| N0 | 110 (23.97%) |
| N1 | 164 (35.72%) |
| N2 | 107 (23.31%) |
| N3 | 78 (17.00%) |
| location of lymph node metastasis | |
| no | 110 (23.97%) |
| perigastric | 159 (34.64%) |
| extragastric | 190 (41.39%) |
| Lauren classification | |
| intestinal | 122 (26.57%) |
| diffuse | 319 (69.50%) |
| mixed | 18 (3.93%) |
| methylated CpG site count | |
| 2 or less | 220 (47.93%) |
| 3 or more | 239 (52.07%) |
| methylated status of CpG +79 | |
| unmethylated | 229 (49.89%) |
| methylated | 230 (50.11%) |